Switch theme
Sign up to access all valuation multiples
Senzime AB is a medical device company providing patient monitoring systems. Its portfolio comprises systems for patient monitoring of neuromuscular function and breathing, typically during and after surgery, and for the intensive care sector. TetraGraph is a system based on EMG technology for neuromuscular monitoring during surgical procedures. ExSpiron 2Xi is a non-invasive monitoring system of respiratory volume and minute ventilation used for in and out patient care. The company operates in Sweden, Germany and the USA. It derives revenue through sales of monitors and associated disposable sensors to hospitals and clinics.
1999
54
LTM Revenue $8.2M
LTM EBITDA -$9.1M
$55.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Senzime has a last 12-month revenue (LTM) of $8.2M and a last 12-month EBITDA of -$9.1M.
In the most recent fiscal year, Senzime achieved revenue of $6.0M and an EBITDA of -$9.9M.
Senzime expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Senzime valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | XXX | $6.0M | XXX | XXX | XXX |
| Gross Profit | $3.5M | XXX | $2.1M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | -$9.1M | XXX | -$9.9M | XXX | XXX | XXX |
| EBITDA Margin | -111% | XXX | -163% | XXX | XXX | XXX |
| EBIT | -$11.8M | XXX | -$13.5M | XXX | XXX | XXX |
| EBIT Margin | -143% | XXX | -224% | XXX | XXX | XXX |
| Net Profit | -$11.3M | XXX | -$12.2M | XXX | XXX | XXX |
| Net Margin | -136% | XXX | -203% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Senzime's stock price is SEK 5 (or $0).
Senzime has current market cap of SEK 619M (or $63.9M), and EV of SEK 541M (or $55.8M).
See Senzime trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55.8M | $63.9M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Senzime has market cap of $63.9M and EV of $55.8M.
Senzime's trades at 9.3x EV/Revenue multiple, and -5.7x EV/EBITDA.
Equity research analysts estimate Senzime's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Senzime has a P/E ratio of -5.7x.
See valuation multiples for Senzime and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63.9M | XXX | $63.9M | XXX | XXX | XXX |
| EV (current) | $55.8M | XXX | $55.8M | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | -6.1x | XXX | -5.7x | XXX | XXX | XXX |
| EV/EBIT | -4.7x | XXX | -4.1x | XXX | XXX | XXX |
| EV/Gross Profit | 15.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.7x | XXX | -5.2x | XXX | XXX | XXX |
| EV/FCF | -4.7x | XXX | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSenzime's last 12 month revenue growth is 95%
Senzime's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Senzime's rule of 40 is -229% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Senzime's rule of X is 127% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Senzime and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 95% | XXX | 94% | XXX | XXX | XXX |
| EBITDA Margin | -111% | XXX | -163% | XXX | XXX | XXX |
| EBITDA Growth | -53% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -229% | XXX | -68% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 127% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 158% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 259% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Senzime acquired XXX companies to date.
Last acquisition by Senzime was XXXXXXXX, XXXXX XXXXX XXXXXX . Senzime acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Senzime founded? | Senzime was founded in 1999. |
| Where is Senzime headquartered? | Senzime is headquartered in Sweden. |
| How many employees does Senzime have? | As of today, Senzime has 54 employees. |
| Who is the CEO of Senzime? | Senzime's CEO is Mr. Philip Siberg. |
| Is Senzime publicy listed? | Yes, Senzime is a public company listed on STO. |
| What is the stock symbol of Senzime? | Senzime trades under SEZI ticker. |
| When did Senzime go public? | Senzime went public in 2008. |
| Who are competitors of Senzime? | Similar companies to Senzime include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Senzime? | Senzime's current market cap is $63.9M |
| What is the current revenue of Senzime? | Senzime's last 12 months revenue is $8.2M. |
| What is the current revenue growth of Senzime? | Senzime revenue growth (NTM/LTM) is 95%. |
| What is the current EV/Revenue multiple of Senzime? | Current revenue multiple of Senzime is 6.8x. |
| Is Senzime profitable? | Yes, Senzime is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Senzime? | Senzime's last 12 months EBITDA is -$9.1M. |
| What is Senzime's EBITDA margin? | Senzime's last 12 months EBITDA margin is -111%. |
| What is the current EV/EBITDA multiple of Senzime? | Current EBITDA multiple of Senzime is -6.1x. |
| What is the current FCF of Senzime? | Senzime's last 12 months FCF is -$12.0M. |
| What is Senzime's FCF margin? | Senzime's last 12 months FCF margin is -146%. |
| What is the current EV/FCF multiple of Senzime? | Current FCF multiple of Senzime is -4.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
